Musoke P - Search Results

1

Enhanced Peer-Group strategies to support prevention of Mother-to-Child HIV transmission leads to increased retention in care in Uganda: A Randomized controlled trial.

Amone A, Gabagaya G, Wavamunno P, Rukundo G, Namale-Matovu J, Malamba SS, Lubega I, Homsy J, King R, Nakabiito C, Namukwaya Z, Fowler MG, Musoke P. Amone A, et al. Among authors: musoke p. medRxiv [Preprint]. 2023 Apr 17:2023.04.15.23288495. doi: 10.1101/2023.04.15.23288495. medRxiv. 2023. Update in: PLoS One. 2024 Apr 19;19(4):e0297652. doi: 10.1371/journal.pone.0297652. PMID: 37131665 Free PMC article. Updated. Preprint.

2

A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006).

Musoke P, Guay LA, Bagenda D, Mirochnick M, Nakabiito C, Fleming T, Elliott T, Horton S, Dransfield K, Pav JW, Murarka A, Allen M, Fowler MG, Mofenson L, Hom D, Mmiro F, Jackson JB. Musoke P, et al. AIDS. 1999 Mar 11;13(4):479-86. doi: 10.1097/00002030-199903110-00006. AIDS. 1999. PMID: 10197376 Clinical Trial.

3

Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial.

Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, Sherman J, Bakaki P, Ducar C, Deseyve M, Emel L, Mirochnick M, Fowler MG, Mofenson L, Miotti P, Dransfield K, Bray D, Mmiro F, Jackson JB. Guay LA, et al. Among authors: musoke p. Lancet. 1999 Sep 4;354(9181):795-802. doi: 10.1016/S0140-6736(99)80008-7. Lancet. 1999. PMID: 10485720 Free article. Clinical Trial.

4

Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission.

Jackson JB, Becker-Pergola G, Guay LA, Musoke P, Mracna M, Fowler MG, Mofenson LM, Mirochnick M, Mmiro F, Eshleman SH. Jackson JB, et al. Among authors: musoke p. AIDS. 2000 Jul 28;14(11):F111-5. doi: 10.1097/00002030-200007280-00001. AIDS. 2000. PMID: 10983633

5

Total lymphocyte count: not a surrogate marker for risk of death in HIV-infected Ugandan children.

Musoke PM, Young AM, Owor MA, Lubega IR, Brown ER, Mmiro FA, Mofenson LM, Jackson JB, Fowler MG, Guay LA. Musoke PM, et al. J Acquir Immune Defic Syndr. 2008 Oct 1;49(2):171-8. doi: 10.1097/QAI.0b013e318183a92a. J Acquir Immune Defic Syndr. 2008. PMID: 18769352 Free PMC article.

6

Predictors of early and late mother-to-child transmission of HIV in a breastfeeding population: HIV Network for Prevention Trials 012 experience, Kampala, Uganda.

Mmiro FA, Aizire J, Mwatha AK, Eshleman SH, Donnell D, Fowler MG, Nakabiito C, Musoke PM, Jackson JB, Guay LA. Mmiro FA, et al. J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):32-9. doi: 10.1097/QAI.0b013e3181afd352. J Acquir Immune Defic Syndr. 2009. PMID: 19617849 Free PMC article. Clinical Trial.

7

Response to antiretroviral therapy in HIV-infected Ugandan children exposed and not exposed to single-dose nevirapine at birth.

Musoke PM, Barlow-Mosha L, Bagenda D, Mudiope P, Mubiru M, Ajuna P, Tumwine JK, Fowler MG. Musoke PM, et al. J Acquir Immune Defic Syndr. 2009 Dec;52(5):560-8. doi: 10.1097/qai.0b013e3181b93a5a. J Acquir Immune Defic Syndr. 2009. PMID: 19950430

8

Considerations in using US-based laboratory toxicity tables to evaluate laboratory toxicities among healthy malawian and Ugandan infants.

Lubega IR, Fowler MG, Musoke PM, Elbireer A, Bagenda D, Kafulafula G, Ko J, Mipando L, Mubiru M, Kumwenda N, Taha T, Jackson JB, Guay L. Lubega IR, et al. J Acquir Immune Defic Syndr. 2010 Sep;55(1):58-64. doi: 10.1097/QAI.0b013e3181db059d. J Acquir Immune Defic Syndr. 2010. PMID: 20588184 Free PMC article.

9

Growth, immune and viral responses in HIV infected African children receiving highly active antiretroviral therapy: a prospective cohort study.

Musoke PM, Mudiope P, Barlow-Mosha LN, Ajuna P, Bagenda D, Mubiru MM, Tylleskar T, Fowler MG. Musoke PM, et al. BMC Pediatr. 2010 Aug 6;10:56. doi: 10.1186/1471-2431-10-56. BMC Pediatr. 2010. PMID: 20691045 Free PMC article.

10

Twelve-month follow-up of Six Week Extended Dose Nevirapine randomized controlled trials: differential impact of extended-dose nevirapine on mother-to-child transmission and infant death by maternal CD4 cell count.

Omer SB; Six Week Extended Dose Nevirapine (SWEN) Study Team. Omer SB, et al. AIDS. 2011 Mar 27;25(6):767-76. doi: 10.1097/QAD.0b013e328344c12a. AIDS. 2011. PMID: 21330912 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

251 results

Search Page